Nautilus Biotechnology (NAUT) versus competitive financial analysis

Head-to-Head Tackle: Nautilus Biotechnology (NAUT) against its peers


Nautilus Biotechnology (NASDAQ: NAUT – Get Rating) is one of 43 publicly traded companies in the “analytical tools” industry, but how does it compare to its peers? We will compare Nautilus Biotechnology with related businesses based on the strength of analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Evaluation and earnings

This table compares the revenues, earnings per share (EPS) and valuation of Nautilus Biotechnology and its colleagues.

Gross Income Net income Price / earnings ratio
Nautilus Biotechnology N / A – $ 50.31 million -6.25
Nautilus Competing biotechnologies 1.19 billion dollars $ 356.47 million -8.18

Nautilus Biotechnology colleagues have higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst recommendations

This is a breakdown of current valuations and target prices from Nautilus Biotechnology and its colleagues, as reported by MarketBeat.

Sell ​​ratings Keep the ratings Buy ratings Strong purchase ratings Evaluation score
Nautilus Biotechnology 0 2 2 0 2.50
Nautilus Competing biotechnologies 320 1326 1831 57 2.46

Nautilus Biotechnology currently has a consensus target price of $ 8.67, indicating a potential upside of 143.45%. As a group, the “analytics” companies have a potential upside of 41.22%. Given Nautilus Biotechnology’s stronger consensus rating and possible higher hike, research analysts clearly believe Nautilus Biotechnology is more supportive than its peers.

Profitability

This table compares Nautilus Biotechnology and its competitors’ net margins, return on equity and asset returns.

Net margins Return on equity Return on assets
Nautilus Biotechnology N / A -15.57% -14.77%
Nautilus Competing biotechnologies -187.73% 3.44% -10.22%

Institutional and privileged property

47.9% of Nautilus Biotechnology’s shares are owned by institutional investors. Comparatively, 61.3% of the shares of all “analytical instruments” companies are owned by institutional investors. 13.3% of the shares of all “Analytical Tools” companies are owned by insiders. Strong institutional ownership indicates that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Nautilus Biotechnology colleagues beat Nautilus Biotechnology on 8 of the 12 factors compared.

Nautilus Biotechnology company profile (Get evaluation)

Nautilus Biotechnology, Inc., a developing life science company, is committed to creating a technology platform to quantify and unlock the complexity of the proteome. Develop Nautilus Platform, a proteomics platform that includes an end-to-end solution consisting of tools, consumables, and software analytics. The company was founded in 2016 and is headquartered in Seattle, Washington.



Receive news and ratings for Nautilus Biotechnology every day – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Nautilus Biotechnology and related companies with MarketBeat.com’s FREE daily newsletter.

.

Leave a Comment

Your email address will not be published.